ETON vs JAZZ
ETON: Eton Pharmaceuticals develops and commercializes rare disease treatments, with a portfolio of ten marketed products and four late-stage candidates targeting ultra-rare genetic and metabolic disorders. JAZZ: A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of innovative treatments.
Side-by-side fundamentals
| Metric | ETON | JAZZ | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $43.58 | $250.41 | |
| Market cap as of 2026-07-23 | $1.2B | $16.0B | |
| P/E as of 2026-07-23 | n/a | 543.13 | |
| PEG as of 2026-07-23 | n/a | 58.02 | |
| Net margin as of 2026-07-23 | -1.7% | +0.7% | JAZZ higher |
| Gross margin as of 2026-07-23 | +54.8% | +88.0% | JAZZ higher |
| Operating margin as of 2026-07-23 | +2.4% | -0.8% | ETON higher |
| ROE as of 2026-07-23 | -5.7% | +0.7% | JAZZ higher |
| ROA as of 2026-07-23 | -1.5% | +0.3% | JAZZ higher |
| Debt / equity as of 2026-07-23 | 1.00 | 1.18 | ETON lower |
| Revenue growth (YoY) as of 2026-07-23 | +79.9% | +9.2% | ETON higher |
| Revenue CAGR (3y) SEC XBRL | +55.5% | +5.3% | ETON higher |
| Beta as of 2026-07-23 | 0.89 | 0.37 | |
| 1-year return as of 2026-07-22 close | +200.0% | +125.7% | ETON higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.